Sleep disord ered breathing was first describ ed in ancient times. It is the result of a three-way interaction between the sleep/wake state-specific mechanisms of respiratory control, the interfa cing ofthese mechanisms during times of state chan ge, and the physical properties of the head and neck. Sleep disordered breath ing results in pathological daytime sleepin ess and is associated with significant cardiovascular morbidity. This pap er reviews the history ofthe field, the physiologic and structuralfactors that result in sleep disord ered breathing, and the implications of these factors for therapy.
ing from hypoventilation during both sleep and wakefulness were believed to be responsible for the observed periodic respiration, polycythemia, and heart failure. Hypox ia and hypercapnia were felt to be the cause of hypersomnolence'
But during the decade that followed, improved technology documented that only a small minority of obese and hype rsomnolent patients were hypoxic or hypercapnic while they were awake. Thi s group represents the true Pickwickian patient. Most obese and sleepy patients were found to have normal blood gases while they were awake. Their hypersomnolence was primarily the result of sleep fragmentation caused by SDB. I Prevalence. Recent data suggest that the prevalence of SDB in the form of obstructive sleep apnea (OSA) is 24% for men and 9% for women between the ages of30 and 60 years. " Approximately 4% of men and 2% of women in that age range have full-blown OSAS , the syndrome being defined by OSA that cause s hypersornnolence." Estimates of the incidence of OSA for elderly men range from 28 to 67 % and for elderly women from 20 to 54 %. [7] [8] [9] [10] [11] Of the approximately 75,000 patients seen annually in accredited sleep disorders centers, 75 % are diagnosed with OSAS . Recent projections ofthe prevalence of OSAS in the United States range from 7 to 18 million people ."
Sequelae. Two primary health consequences are associated with OSAS . 12 One is the neuropsychiatric sequelae of chronic sleep disruption, which include depression, cogn itive dysfunction, disruption of professional, family, and social life, and inattention that can result in automobile and industrial accidents. The second is the cardiovascular sequelae of chronic sleep-related hypoventilation, which include pulmonary and systemic hypertension, congestive heart failure, coronary heart disease, myocardial infarction, and stroke. Industrial safety and transportation authorities are currently focusing on hypersornnolence as a significant cause of industrial and mass transportation accidents, and the incidence of recurrent highway crashes is seven times greater for individuals with OSAS than for normal controls. P:" Natural history studies demonstrate an association be- tween snoring or OSA and hypertension, cardiac ischemia, myocardial infarction, and stroke. In many studies, the strength of these associations is dim inished when findings are adjusted for the potentially confounding influences of obesity and smoki ng, which could both independ ently increase the risk of vascular disease, snoring, and SDB . one case -control study that attempted to control for weight and smoking, the risk of myocardial infarction was four times higher among snorers than nonsnorers, while weight and smoking did not appear to be confounding factors. IS Another study of patients with OSAS found that they had twice the prevalence of hypertension , three times the prev alenc e of co ronary arte ry disea se, and four times the prevalence of cerebrovascular disease than did the U.S. population in general as reported by the National Cent er for Health Statistics." In a report of a 5-ye ar follow up of 198 patients with OSAS, the overall mortality for pati ents who had been treated "conservatively"-that is, they were prescrib ed a weig ht loss regimen-was I I %. 20 By contrast, there were no deaths among patient s in whom OSAS was eliminated by tracheostomy , despite the fact that the tracheostomi zed patient s had been more seve rely affected. In a study of385 OSAS patients with 8-year followup, overall mort ality was five times higher in untre ated patients who se apnea index was greater than 20 events per hour than for untreated patients whose inde x was less than 20 events per hour. Th ere were no deaths among patients who were effectively treated with tracheostomy or nasal continuous positiv e airway pressure (CPAP). 21 Most studies that have atte mpted to est imate OSAS mortality have been criticized fortheir small sample sizes, short followup, failure to control for confounding variable s associated with obesity or smoking, and other shortcomings inherent in retro spective natural history studies. Changing patterns of treatment have complicated the assessment of the untreated disord er. The weaknesses of various rep orts in the liter atur e were addressed in a recent epide miologic review." To put into perspecti ve the strengths and limit ation s of ex isting data, which sugges t that there are indeed significa nt mortality and morbidity from OSAS , the National Heart, Lung, and Blood Institute recentl y funded the Sleep Heart Health Stud y. Th is investigation is an extensive multicenter, multi year prospective study of the morbidity and mortality caused by OSA.
Varied manifestations of SOB
SDB enco mpasses a numb er of related respiratory disorders that are linked to the sleep state. They are characterized by recurrent episodes of cessation of ventilation (apneas) or respiratory efforts that result in abnormally dimini shed ventilation (hypopneas). Apnea might be the result of a lack of inspiratory effor t, called central apn ea, or of ineffective inspiratory effort against a collapsing upper airway, called obstructive apnea. Obstructive ap-Volume 78, Number 9 nea that is charac terized by an initial ce ntral component followe d by a collapse of the upper airway at the onse t of respi ratory effort has been termed mixed apnea.
Hypopnea also might be central or obstructive in nature. Th e distinction between ce ntral and obstruc tive hypopnea is most effectively made by intraeso phageal manometry, which is generally not performed durin g routine sleep studies. Definiti ons of hypopnea have varied, but all are based on the same parameters: a variabl y dimini shed airflo w that results in a drop in oxyge n saturation of a pre-establi shed degree, a tran sient arousal, or both. Apnea and hypopnea both cause arousal. It was recently demonstrated that inspiratory effort in the face of increased upper airway resistance could result in transient arou sal despite the maintenance of normal ventilation and oxyg enation. The term respirat ory effort-related arou sal (RERA) can be applied to the phen om enon of inspiratory effort aga inst increa sed upper airway resistance that results in transient arousal, eve n though it does not meet the ventilation crite ria of eith er apnea or hypopne a." RER As are the pathognom onic eve nts that define the upper airway resistance syndrome (UARS), which is manifested by the hypersomn olence that is the result of frequent RERA s. 24
Role of the ventilatory control system
There are state-related differences in respiratory cont rol between the sleep and wake states and between the five stages of slee p, most predomin antl y between stages I through 4 non-rapid eye movement (NREM) and rap id eye movement (REM ) sleep. Therefore, the transition fro m one of these states to another involve s a shift in the neu ral and neuromuscular mechani sms that maintain alveolar ventil ation . Thi s modulation includes alterati on s in the complex feedback loops and reflexes that monitor the demands of the org anism and cont rol ventilation to meet its metabolic needs. It also involves state-specific change s in respiratory load compensation in the form of variations in the medull ary motor output to primary and accessory respiratory muscles in response to upper airway resistance and chan ges in resis tance . Breathin g disturbances ofa central, obstructi ve, or mixed nature can occ ur at the interface of two states (e.g., between wake and sleep or between different stages of sleep) in response to the changing state-specific nuances of respiratory cont rol. The respiratory instability preven ts the smoo th passage from one state to another, thereb y causing a volley of shifts back and forth across the two interfaces. This perpetu ates instability in both respi ration and the state." ?" Wake and NREM sleep generally interface. Sleep is the more vulnerable condition with res pect to the body ' s ability to adapt to metab olic dem and s. Durin g wakefulness, the brain almost anticipates metabolic rate demands and provid es rapid comp ensation for changes in breathing that are' brought about by altered requirements for gas 695 SHER exc hange . A strong functional compo nent of the drive to breathe in wakefulness, referre d to as the wakefulness drive, might reside within the reticular activating system of the forebr ain. The wakefulness dri ve responds to visual, acoustic, and soma testhetic stimuli and is free of metabolic influ enc e. It serves to boost the respiratory drive that is modul ated by the chemoreceptor feedback system. The chemoreceptor system depend s on the integration of input from the central pH and PaCO z chernoreceptors; the periph eral PO z and PaCO z chemoreceptors; the lung, chest wall, and upper airway mech anorec eptors; pressure receptors; and possibly flow receptors. The transition from wakefulness to sleep deactivates the wakefulness dri ve, thu s makin g respiratory control more dependent on chemoreceptor feedb ack . Thi s results in a diminished responsiveness to blood gas alterations. The absence of the wakefuln ess drive makes the body more vulnerable to ventilatory instability." :"
The setpoint for PaC0 2 is higher durin g sleep than wakefulness, and the hypercapni c ventilatory response curve is shifted to the right throughout all stages of sleep as co mpared with wakefulness. The slope, or gain, of the ventilatory res ponse to hypercapn ia is dimini shed durin g sleep comp ared with wakefulness . These changes durin g sleep onset might actually reflect the reacti vation of the chemorece ptor system, which is pre-empted dur ing wakefulness by the wakefulness drive.
At the moment of sleep onset, the PaC0 2 setpoi nt is raised from the wake PaC0 2 setpoi nts to the higher sleep PaC0 2 setpoint. At the instant that the setpoint is reset, the static PaCO z remains transientl y below the newly established sleep setpoint (at the level determined durin g the immediat ely ended period of wakefulness). The static PaC0 2 , still at the lower wake level, is sensed as relative hypocapnia and triggers marked ventilatory inhibition. An apneic event ensues, durin g which the relative hyp ocapnia is corrected as PaC0 2 rises to meet the sleep setpoint. The apnea results in hypo xia, which triggers a vigorou s respirator y response to correct the hypoxia. It also ca uses a brief arousal (" microa rousal") that terminates the apnea . The microarousal instantly lowers the PaC0 2 setpoint back down to the wake setpoint. PaC0 2 , in the ensuing breaths, is driven down to a level co mmensura te with the transiently reestablished wake state. As this occ urs, sleep is rees tablished. The corrected PaC0 2 once agai n is below the reesta blished sleep setpoin t, and respiratory inhibition and apnea rec ur. Simil ar transie nt decreases in PaC0 2 below its corresponding wake setpoint would not result in respiratory inhibitio n and apnea in the wake state because inhibition would be overridden by the wakefulness dri ve to breathe. However, because the relative hypocapnia occurs during transitions into sleep, when there is an absence of the wakefulness dri ve, significant respiratory inhibition to the point of apnea ensues.P?"
In summary, perpetuation of periodi c breathing and 698 ce ntral apnea or hypopnea occurs as a result of the mutu al interac tion of the dynam ically changing sleep/wake states and the corresponding modul ations in respiratory control that occ ur with shifts from one state to ano ther. The cyclical shifts in state (fro m wake to sleep to wake and back) are brought about by respi ratory control instability, which is set in moti on by the initial shift from wake to sleep. Each apneic peri od is term inated by an arousal o r m icr o arou s al (t he latt er is d o cumented by electroencephalography; it is not usually consciously perceived by the indi vidual). The breath immediately followin g the arousal is a large, compensatory breath that is stimulated I) by the asphyxic stimulus (asphyxia resulting fro m the preceding apnea ), 2) by the increased gain attributable to the shift in PaC0 2 from its position below the sleep PaC0 2 setpoint to its new position above the wake PaC0 2 setpoint, and 3) by the introduction of the wakefulness dri ve to breathe coincident with arou sal. Thi s large breath lowers PaC0 2 • Apnea does not occur durin g the brief epoch of wakefulness , but the microarou sal termin ates quickly with a rapid return to sleep. With the resumption of sleep, PaC0 2 once again is belo w the sleep setpoint and apnea threshold. These co nstantly and cyc lically shifting states-that is, from preapn eic to postapneic, and from sleep to wake fulness, with the resultant switches in respiratory control setpoints and gains-perpetuate the cyclic apneas by prevent ing the respirator y cont rol system from attaining and maintaining a state ofequilibrium. . Th is seco ndarily perpetuates state instability.
The transition s from wakefulness to sleep and from NREM to REM sleep also place the indi vidual at risk for hypoventilation as a result of sleep-related impairment of strategies for compensatin g with upper airway load (upper airway resistance) comp ensation . The negative pressure required for inspiration is generated through an increa se in chest cavity volume by actions of the diaphragm and intercostal muscles. Upper airway respiratory muscle acti vity pro vides compensatory "s tiffening" of the upper airway to pre vent a decrease in the size of the pharyngeal lumen and an increase in resistance to airflow. Reflex arcs invol ving these upper airway dilator muscles are integrated with the cent ral mechanisms that control vent ilation and breathing. The geniog loss us muscle, for instance, respond s to chemoreceptor stimuli by contracting in order to increase upper airway patenc y. Data suggest that there are several types of reflexes that control the upper airway musculature, with affe rent input from chemorece ptor, postur al, and pressure receptors. Thi s co mpensatory action is dimini shed dur ing the sleep state compared with wakefulness. It is maxim ally dimini shed during REM sleep, when there is extreme skeletal muscle hypotonia or atonia . Alth ough dur ing wake fulne ss the intensity of motor output to the pharyngeal dilator muscles increases rapidly when needed to compensate for increa sing upper airway resistance, sleep impairs the cornpen sa-ENT-Ear, Nose & Throat Journal> September 1999 tory increase in neural drive, and REM sleep imp airs it the most. Th e degree of altera tion depends on the specific stage of slee p, with REM-related hypotoni a more profound than NREM. It can be generalized that in normal sleep-re lated breathin g, the pharyngeal airway is not fully protected from the effec ts of inspiratory negative pressure by comp ensatory upper airway muscle action. As a result , norm al sleep triples the upper airway resistance compared with wakefulness.P-" GS A represents the most extreme degre e of lack of compensation for increa sed upp er airway resistance , and it is characterized by upper airway collapse uncompensated by dilator muscle action. Collapse occurs in the phar ynx . Coll ap se can occ ur in the retrop alatal or retroglossal port ions of the pharynx, or both. The site of pharyngeal obstruction var ies amo ng patients. Although airway resistance increases in norm al persons durin g sleep as compared with wakefulness, the sleep-related increase is three times greater in individuals with GS A than in normals. An obstructive apnea result s in an arousal or microarousal, with a return to the awake pattern of homeostasis. The wakef ulness drive establishes adequate compensation for the increa se in upper airway resistance throu gh dilator muscle action, and the obstructive apne a terrninates.P:"
Primary neur ologic or neuromu scular pathology occ asionally results in GSA ; such pathologies include Chiari malformati on, syringomyelobulbia, cerebral palsy, myotonic dystroph y, Sh y-Drager syndro me, acq ui re d nonp rogre ssive dysauton omia, olivoponto cerebellar degeneration, spinal cord injur y, and bulb ar stroke. However, in most cases of GS A , there is no identifiable neuromu scul ar dysfunct ion, and the problem relates primarily to the increase in upper airway resistance."
Role of upper airway anatomy and structural variation in SOB Anatomic abnormalities. Increased upper airway res istance and collapsibility in patient s with GSA can be the result of an anatomic compromise. Phar yngeal resista nce durin g wakefulness is increased in GSA patients compared with normal cont rols, and pharyngeal resistanc e correlates with GSA severity.P v" The pharynx of adults with GS A collapses when ex perimentally exposed to subatmospheric pressure during wakefulness, whereas that of norm al controls does not ." The upper airway is Address: . anatomically smaller in apneics than in normals, especially at the retropalatal and retroglossal levels." :" Pharyngeal cross-sectional area correlates inversely with GSA severity." GSA has been associated with anatomic compromise resulting from neoplasia (benign or malignant), metabolic abnormality, and traumatic compromise.Infiammatory and metabolic disorders might cause diffuse enlargement of such structures as the tongue and pharyngeal lymphoid tissues, resulting in a compromise of the airway." However, in the vast majority of cases, no specific focu s of upper airway pathology can be identified. In one study of 200 patients with GSA, only three had a single pathological anatomic problem ." The rest demonstrated a combination of "disproportionate anatomic relationships" in the upper airway.
Many well-defined craniofacial abnormalities can cause GSA.39The angles and distances within the upper airway (i.e., the dimensions and configuration of the pharyngeal airway) and the vectors of action of the airway's supporting muscles are determined by the dimensions and spatial relationships of the underlying craniofacial skeleton. Frequently, the anatomic basis for the upper airway obstruction is multifactorial, involving complex skeletal abnormalities translated into pharyngeal soft tissue abnormalities . Several abnormal patterns of craniofacial development have been recognized in adults who were previously considered to be morphologically normal but who manifested GSAS. 39 In a study of craniofacial bony landmarks in lateral cephalograms (radiologic studies of craniofacial skeletal and soft tissue structures) of patients with GSA, 153 of 155 patients had at least two abnormal landmarks." There were many similarities between these findings and those in the population with specifically defined craniofacial syndromes."
Obesity. The association between GSA and obesity is well recognized. Many (but not all) adults with GSA are somewhat obese. It has been demonstrated that patients with GSA who are not obese have more severe craniofacial abnormalities documented on cephalometry. Those who are morbidly obese tend to have few abnormal cephalometric measurements. The largest group of GSA patients has an intermediate level of obesity and an intermediate degree of cephalometric abnormality."
It is well known that weight gain in a patient with GSA results in an increase in the severity of apnea. It has long been hypothesized, and later documented by MRI, that the region surrounding the collapsible segment of the pharynx in patients with GSA has a greater fat load than doe s the same region in equally obese patients who do not have GSA }?This finding-in conjunction with the finding of an increase in airway resistance and a decrease in airway stability documented when applying lard-filled bags to the neck to simulate cervical fat accumulationsuggests that the effect of obe sity on GSA might be related 700 to local parapharyngeal fat deposits.":" Histopathologic studies of uvulas excised during uvulopalatopharyngoplasty for GSA demonstrated a higher amount of both fat and muscle mass compared with those seen during normal postmortem studies. "
It is hypothesized that GSA results in part from craniofacial dysmorphia of varying severity. The most severely dysmorphic patients, recognized early as having anomalous craniofacial development, present with airway obstruction at birth or during infancy. Those of this group who are the most severely affected have varying manifestations of airway obstruction while awake and asleep. Those who are less severely affected have only GSA. Mildly dysmorphic patients might develop GSA later in life, either as children when hypertrophic tonsils and adenoids tip the balance in favor of frank GSA, or as adults when weight and cervical fat deposition reach a critical point that converts incipient GSA (i.e., snoring or UARS) into frank GSA. 39 The amount of muscle force needed to maintain airway patency in the face of negative pressure applied to the pharynx relates both to the degree of the negative pressure applied and to the dimensions and configuration of the pharynx. There are several interacting mechanisms by which a focus of upper airway narrowing predisposes to airway collapse, depending on the region of the upper airway that is compromised. A structural narrowing at the oropharyngeal or hypopharyngeal levels increases the tendency for airway collapse directly by increasing airway resistance. Maintenance of normal tidal volume in the face of increased upper airway resistance requires increased negative inspiratory pressure and increased velocity of air passing through the site of the narrowing. The latter further reduces intraluminal pressure (Bernoulli effect) and increases the tendency for pharyngeal collapse at the site of the narrowing ."
Recent data indicate that a pharyngeal configuration such that the anterior-posterior axis is longer than the lateral-lateral axis promotes airway collapse, although the mechanism has not been explained.":" Stenosis of the nasal or nasopharyngeal airway exacerbates a tendency for GSA through a more complex mechanism of action. At rest, humans normally breathe through the nose . The mouth is held closed by the action of the medial pterygoids, masseter, and temporalis muscles. The normally high resistance of the nose in transnasal inspiration results in the introduction of subatmospheric intrapharyngeal pressure, and the transmural pressure of the pharynx tends to close the airway. If the nose is abnormally constricted, the resistance to airflow will be higher, and the pharyngeal negative pressure will be greater. This will more strongly tend to bring about pharyngeal occlusion." Many individuals who snore or have GSA mouthbreathe during sleep. Although this has not been systematically investigated, increased nasal or nasopharyngeal
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C'TAR/TING! Adverse events report ed in pl acebo-controlled chronicidiopathic urti caria trial s were simi lar to those reported inallergicrhinitis studies.
Adverse event rat es did not appear to diff ersignificantly based onage, sex, or race,although the numberof nonwhitesubjects was rel ativel y small. CLARITIN REDITABS (Ioraladine rapidly-disinlegraling tablets): Approximatel y 500 patient s received CLARITINREDITABS (Ioratadinerapidl y-di sintegrating tablets) in controlledclinical trial s of 2 weeks' dur ation. Inthese studies, adverse eventsweresimilar in typeand frequency to thoseseen with CLARITINTablets and pl acebo.
Administration of CLARITIN REDITABS(Ioratadine rapidly-disint egr ating tabl et s) did notresul t in an increased reporting frequency of mouth or tongue irritation.
ClARITIN Syrup : Approximately 300 pediatric patients 6 to 12 years of age received 10mgloratadineonce dail y in controlled clinical trial s tora peri odof 8-15 days. Among these, 188 children were treated with 10 mg lorat adine syrup once dail y in pl acebo-controll ed trials. Adverse eventsin these pedi atri c patients were observed to occurwith type and frequency similar to those seen in the adult populati on. The rate of premature discontinuance due to adverse eventsamong pediatricpatients receiving loratadine10mgdail y was less than1%. In addition to those adverse events reported above (~2%), the following adverse events have been reported inat least one patientin CLARITINclinical trial s inadult and pediatric patients:
Autonomic Nervous System: Altered lacrimation, altered salivation, flushing, hypoesthesia, impotence, increasedsweating,thirst.
Body As A Whote: Angioneurotic edema, asthenia, back pain, blurred vision, chest pain, earache, eye pain, fever, leg cramps, mal ai se,rigors, tinnitus, viral infection, weightgain.
CardiovascularSystem: Hypert ension, hypotension, palpitations, supraventricular tachyarrhythmias, syncope, tachycardia.
Central andPeri pher al Nervous System: Bl epharospasm, dizziness, dysphonia, hypertonia, migraine, paresthesia, tremor, vertigo.
Gastrointestinal System: Altered taste, anorexia, constipation, diarrhea, dyspepsia, flatulence, gastriti s, hiccup, increased appetit e, nausea,stomatitis,toothache, vomi ting.
Muscul oskel et alSystem: Arthralgi a, myalgia. Psychiatric: Agitation, amnesia, anxiety, confusion, decreased libido, depr ession, impairedconcentration,insomnia, irritability,paroni ria.
Reproducti veSystem: Breast pain, dysmenorrhea, menorrhagia, vaginitis. Respir atol}'System: Bronchiti s, bronchospasm, cou ghing , dyspnea, epistaxis, hemoptysis, laryngitis, nasal dryness, pharyngitis,sinusi tis,sneezing.
Skin andAppendages: Dermatitis, dryhair, dryskin,photosensitivityreaction,pruritus, purpura, rash, urti caria.
Urinal}' System: Altered micturit ion, urinary discoloration, urinary inconlinence, urinary retention.
In addition, the following spontaneousadverse events have beenrep orted rarel y during themarketing of loratadine: abnormal hepati c function, including jaundice, hepatiti s, and hepatic necrosi s; alopecia; anaphylaxis; breast enlargement; erythema multiforme; peripheraledema; and seizures. OVERDOSAGE: In adults, somnolence, tachycardia, and headache have been reported with overdoses greater than 10mgwith theTabletformulation (40to 180mg). Extrapyramidalsignsand palpitali ons have been reported in children with over doses of greaterthan 10mgof CLARITINSyrup. In the event of overdosage, general symptomatic and supportive measures should be instituted promptly and maintained foras long asnecessary.
Treatment of overdosage would reasonably consist of emesi s (ipecac syrup), except in patients with impaired consciousness, followed by the administration of activated charcoal to absorb any remaining drug. II vomiting is unsuccessful, orcontrai ndicated,gastriclavageshould be performed with normal saline. Saline cathart lcs may also beof value for rapid dilution of bowel contents. Lor atadineis not eliminated byhemodial ysis.It is not knownif lorat adine is eliminated byperitoneal di al ysi s.
Nodeaths occurred at oral doses upto 5000 mglkgin rats and mi ce (greaterthan 2400 and 1200 times, respectively,the maximumrecommended humandaily oral dose ona mg/m 2 basi s). Single oral doses of loratadine showed noeffects in rats, mi ce, and monkeys atdoses as high as10times themaximum recommended human dail y oraldose ona mg/m 2 basi s.
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Brief Summary (For Full Prescribing Informalion , see package insert). INDICATIONS AND USAGE: CLARITIN is indicated for the reli efof nasal and non-nasalsymptoms of seasonal al lergic rhinitis and for thetreatmentofchronicidi opathic urti cari a in patients 6 yearsof age or older. CDNTRAINDICATIONS: CLARITIN is contrai ndicated in pati ent s who are hypersensilive to this medi cationor toany of itsingredients. PRECAUTIONS : General : Patients with liver impairment or renal insufficiency (GFR < 30 mUmin) should be given a lower initial dose (10 mg every other day). (See CLINICAL PHARMACOLOGY: Special Populalions.)
. . . . Drug Inleraclions: l orat adine (10 mg once daily) has been coadml otstered with therapeutic doses of erythromycin, cimetidine, and ketoconazole in controlled clinical pharmacology studies in adult volunteers. Although incr eased pl asma concentrations (AUC 0-24 hrs) of loratadine and/or descarboethoxylorat adinewereobserved foll owing coadmi nistration of lorat adinewith each oft hese drugsin normal volunteers (n = 24 in each study), there wereno clinically rel evant changes In the safety profil eofloratadine,as assessed byelectrocardiographic par ameters, clinical laboratorytests, vital signs, and adverse events. There were no significant effects onOleintervals, and no reports of sedation or syncope. No effects on plasma concentrat ions of cimetidine or ketoconazole were observed. Pl asma concentrations (AUC0-24 hrs) of erythromycin decreased 15% with coadministration of loratadine relative to that observed wi th eryth romycin alone. The clinical rel evance of thi s differenceis unknown. Theseabove findings aresummarized inthe foll owingtable:
EffectsonPlasmaConcentrations(AUC0-24 hrs) of Lorat adineand Descarboethoxyloratadine After 10 Daysof Coadministrati on (Loratadine10mglin NormalVolunteers Descarboethoxylorafadine Erythromycin (500 mgQ8h) + 40% +46% Cimetidine(300mg QID) +103% + 6% Ketoconazole (200mg Q12h) +307% +73% There does not appear to be an increase in adverse events in subjects who recei ved oral contraceptives and lorat adine.
Carcinogenesis, Mutagenesis, and Impairment of Fertility: In an 18-month carcinogenicity study in mice and a 2-year study in rats, lorat adine was admi nistered in the diet at doses up to 40 mglkg (mice) and 25mglkg (rats). In thecarci nogenicity studies, pharmacokinetic assessments werecarried outto det ermine animal exposure to the drug. AUC data demonstrated thatthe exposure of mice given 40 mglkg of lorat adine was 3.6 (Ioratadine) and 18 (descarboethoxyloratadine) times hi gher than in humansgi venthe maximum recommended dail y oral dose. Exposur e of rats gi ven 25 mglkg of lorat ad ine was 28 (lorataclne) and 67 (descarboethoxyloratadine) times higher than in humans giventhemaximum recommended dail y oraldose. Mal emicegi ven 40mglkghada significantly higherincidence of hepatocellular tumors (combined adenomas and carcinomas) than concurrent controls. In rats, a signi ficantly higher inci dence of hepatocellular tumors (combined adenomas and carci nomas) was observed in mal es given 10 mglkg and mal es and femalesgiven 25 mg/kg . The clinical significance of these findings during long-term use of CLARITIN is not known.
In mutagenicity studies, there was no evidence of mut agenic pot ential in reverse (Ames) or forward poi nt mutation(CHO-HGPRT) assays, or in theassay for DNA damage(rat primaryhepatocyte unscheduled DNA assay) or in twoassays for chromosomal aberrations (human peripheral bl ood lymphocyte clastogenesis assay and the mouse bone marrow erythrocyte micronucleus assay). In themouse iymph oma assay, a positive finding occurred in the nonacti vated but notthe activated phaseof the study.
Decreased fertilityin mal e rats, shown by lower femal econception rates, occurred at an oraldose of 64 mglkg (approximately 50 times the maximum recommended human daily oral dose on a mg/m 2 basis) and was reversible with cessation of dosing. loratadine had no effect on mal e or femal efert ility or reproducti onin the rat atan oral dose of approximately 24mglkg (approximately 20times the maximum recommended human dail y oral doseona mg/m 2 basis).
Pregnancy Category B: There was no evidence of animal teratogenicity in studiesperf ormed in rat s and rabbits at oral doses upto 96mglkg (approximatel y 75 times and 150times, respectivel y, themaximum recommended humandail y oral doseona mg/m 2 basis). Thereare, however, noadequate and well-controlled studies in pregnant women. Because animal reproductionstudies arenot always predictive of human response, CLARITIN should be used during pregnancy only if clearly needed.
NursingMothers: Lor atadineand its metabolite,descarboethoxyloratadine, pass easilyinto breast milkand achieve concentrat ions thatareequivalent to plasma level s withan AUCm Hl /AUC,'" ma rati o of 1.17 and 0.85for loratadine and descarboethoxyloratadine, respectively. Following a single oral dose of 40 mg, a small amount of loratadine and descarboethoxyloratadine was excreted into the breast mil k (appmximately 0.03% of 40 mgover 48hours). Adecisionshould be madewhether to discontinue nursi ngor to discontinuethedrug, taking int o account theimportanceofthe drug tothe mother. Cautionshould beexercisedwhen CLARITINisadministeredto a nur sing woman.
Pediatric Use: The safety of CLARITINSyrup at a dail y dose of 10mghas beendemonstrat ed in 188 pediatric patients 6-12 years of agein pl acebo-controll ed 2-week trials. The eff ectiveness of CLARITIN forthe treatment of seasonal allergic rhi nilis and chronic idiopathic urticariain this pediatric age group is based on an ext rapolation of the demonstrat edefficacy of CLARITINin adults in these condi tionsand the likelihoodthat the disease course, pathophysiology, and the drug's effect aresubstantiallysimilar to that of the adults. The recommended dose forthe pediatric populationis based oncross-studycomparison of the pharmacokinetics of CLARITIN inadults and pediatric subjects and onthe safety profile of loratadine in both adultsand pediatri c pati ent s atdoses equal to or higherthan the recommended doses. Thesafety andeffectiveness of CLARITINin pediatri c patients under 6 yearsofage have not been established. ADVERSE REACTIONS: CLARITIN Tablets: Approximately 90,000 patients, aged 12 and older, recei ved CLARITI N Tabl ets 10 mg once dail y in controlled and uncont roll ed studies. Pl acebocontrolled clinical trial s at the recommended dose of 10 mg once a day varied from 2 weeks' to 6 months' duration. The rate of prematur e withdrawal from these trial s was approximately 2% in boththetreated and pl acebo groups.
REPORTED With the mouth open, the tongue and soft palate are exposed to atmospheric pressure. This releases the anterior part of the tongue, producing a dorsal motion of the belly of the genioglossus, and decreases the dimensions of the oropharyngeal lumen. The entire transmural pressure of the pharynx (atmospheric pressure to relatively negative pharyngeal pressure) is exerted across the soft palate, moving it dorsally and narrowing further the oropharyngeal lumen. 35.53.54 Open mouth posture further compromises the pharyngeal airway by diminishing the length of the axis of action of the genioglossus and, therefore, its efficacy in pulling the tongue forward out ofthe airway. 35 Furthermore, the nasal mucosa, which is bypassed in mouth breathing, might have receptors that respond to airflow and serve as afferent stimuli for the neural regulatory mechanisms of respiration. Eliminating this afferent input to reflex arcs involving upper airway muscles could predispose to OSA. 55, 56 Several clinical studies confirm that nasal obstruction exacerbates a tendency toward OSA. [53] [54] [55] [56] [57] [58] [59] [60] [61] The larynx, the other high-resistance structure in the upper airway, can be the site of OSA when compromised by space-occupying . lesions or abductor paralysis. The efficiency of the action of upper airway dilating muscles-such as the genioglossus, geniohyoid, palatoglossus, palatopharyngeus, stylopharyngeus, and tensor palatini-depends on the proper coordination of their contraction with that of the diaphragm, the vector angles through which they act , and the linear distance through which they contract. The latter two parameters relate to the craniofacial skeletal anatomic attributes of the individual patient.
Anatomic compromise of the craniofacial skeleton and upper airway requires augmented activity from the dilating muscles of the upper airway to maintain airway patency." It has been demonstrated in English bulldogs that upper airway compromise requires abnormally elevated levels of pharyngeal muscle activity to maintain pharyngeal patency during wakefulness. The normal decrease in muscle tone during sleep (down from the elevated levels during wakefulness) might be the mechanism by which OSA occurs in patients who have anatomic upper airway compromise. Although abnormally elevated muscle tone maintains airway patency during wakefulness, muted neuromuscular tone fails to maintain patency during sleep.28.62 collapse can be expressed quantitatively in terms of a critical pressure (Pcrit), which is the pressure surrounding the area of collapse. If atmospheric pressure is designated zero, then airway collapse will occur whenever Pcrit is a positive number (indicating that it is higher than atmospheric pressure). When Pcrit is higher than atmospheric pressure, complete pharyngeal obstruction occurs in the form of obstructive apnea. Pcrit for an OSA patient can be defined as the lowest level of nasal CPAP at which airflow is maintained. OSA is the result of an abnormally elevated Pcrit during sleep." In normals, Pcrit during sleep is -13 em H 20. This means that during sleep, the atmospheric pressure is greater than the Pcrit, and the pharynx will not collapse. In patients who have frank airway collapse during sleep (i.e., OSA patients), Pcrit during sleep is +2 .5 ern H 20. 31,47.63Because Pcrit exceeds atmospheric pressure (defined as zero), pharyngeal collapse will occur. Patients who have varying degrees of partial pharyngeal collapse have intermediate, but negative, levels of Pcrit during sleep: -6.5 em Hp for asymptomatic snorers and -1.6 ern H 20 for patients with hypopneas but no apneas .v -" Pcrit levels are higher during sleep than during wakefulness in both normal individuals and OSA patients. In normals, Pcrit rises from awake values that are more negati ve than -41 ern Hp to sleep val ues of -13 ern H 20 . 31 ,40.64 In OSA patients, the spectrum of awake values of Pcrit ranges from -40 cm H 20 to -17 ern Hp.31 ,4() This means that the pharyngeal airway of OSA patients tends to be more collapsible than that of normals, although these values do not cross the critical line of zero (i.e., atmospheric pressure) except when the individual has sleep onset. The fact that both normals and apneic patients experience a substantial increase in upper airway collapsibility with sleep onset implies that sleep is a vulnerable state for the upper airway." Although the cause of pharyngeal collapsibility in OSA is not clearly defined, it is probably mult ifactorial and reflects a combination of neuromuscular and anatomic variables or abnormalities. It appears clear that sleep-related depression of neuromuscular function and alteration of reflex control of pharyngeal muscles result in marked increases in upper airway collapsibility and elevation in pharyngeal Pcrit in normals, snorers, and patients with OSA and UARS.31.65.67
Pathophysiology
Assessment and therapy for SOB: Mandate for a multidisciplinary team
Nonsurgical treatments for OSA and UARS include behavior modification, pharmacologic therapy, and the use of mechanical devices such as nasal CPAP and intraoral dental devices.
Behavior modification. Relevant forms of behavior modification include sleep hygiene to minimize exogenous sleep deprivation, avoidance of alcohol and sedative medications, efforts related to avoiding the supine 703 SHER sleep position, and efforts related to weight reduction. Sleep deprivation, alcohol, sedative medications, excess body weight, and the supine position all tend to exacerbate OSA and UARS. Sleep hygiene and avoidance of alcohol and drugs prevent exacerbation of OSA and UARS rather than treating the underlying disorder. Although weight reduction is curative in some obese patients with UARS or OSA of all degrees of severity, permanent loss of significant excess body weight by behavioral means alone is rarely successful.tv" Pharmacologic therapy. Drug therapy is generally of limited value in the treatment of OSA . Although there are reports oflimited improvement with acetazolamide, nicotine, and strychnine, none of these agents has proven to be of great value." Of somewhat greater importance are medroxyprogesterone and the tricyclic antidepressant protriptyline, although both are still of limited clinical value . Medroxyprogesterone increases ventilatory response to both hypercapnia and hypoxia in normal men. Although it has been effective in improving oxygenation and correcting hypercapnia in patients with obesity hypoventilation syndrome, it has not proved to be clinically useful in the treatment of normocapnic OSA pa-tients .?"?' Protriptyline appears to ameliorate OSA via two mechanisms: I) it tends to suppress REM sleep , the stage in which muscle hypotonia and OSA severity might be at their greatest, and 2) it increases pharyngeal neural activity and dilates the pharyngeal airway. l' :"
Mechanical devices. Nasal CPAP is widely used as a therapy for OSA (and sometimes UARS) , and it has been regarded as the mainstay of therapy for several years. Through the application of positive pressure to the pharynx via the nose, nasal CPAP has the potential to eliminate OSA. Proper application is based on overnight titration to the patient-specific effective pressure level. The major problem with nasal CPAP is relatively poor patient compliance. Early reports of nasal CPAP compliance were based solely on subjective patient reports, which suggested that long-term compliance rates were between 50 and 90%.70 However, objective monitoring of patient compliance with nasal CPAP reveals significant discrepancies between it and subjective patient reporting and suggests that the level of compliance is much lower than what was previously accepted. In one study, 76% of patients exaggerated their nightly compliance." Only 6% of them used the device for 7 hours per day on at least 5
Mirage~Mask
HumidAire" heated humidifier Th ere is a growi ng interest in devices that affect pharyngea l mechani cs by altering the relative position of the maxilla, mandible, and tong ue. Although the role of these appliances has not been adequa tely delinea ted, they are effec tive in dimini shin g snoring and apnea in some patients.l' :"
Surgery. Surgical approac hes to treat GSA fall into four categories. The first category includes surgical approaches that dire ctly augment the compromised upper airw ay. The se approaches include remov al of tumors or masses, corrective nasal surgery, tonsillectomy, uvulopalatopharyn goplasty, laser-assisted uvulop alatoplasty, laser lingual re section of the ton gu e and lin gualpl ast y, geniog loss al advancement , hyoid suspension, mandibular advancement, and maxill omandibular advancement. A new application of radiofrequ ency energy to ablate porti ons of the palate and tongue base has shown promi se. Th e proc edures must be applied based on a thought ful analysis of the specifi c areas of anatomic compro mise in each patient. In complex cases, multipl e surgical correc-tions must be undertaken, either simultaneously or sequenti ally. Th is comprehensive approac h, based on anatomic assessment, appears to have a high potential for correcting the compro mised upper airway, thereby eliminating GS A, 76-S0 The second surgica l approac h entails surgery to byp ass the upp er airway obstruction (i.e., tracheostomy). Long regarded as the gold standard agai nst which all other treatments were compared, tracheostom y remains a highl y effec tive treatment. Its major limit ations are the physical and psychosocial drawbacks of having a perman ent tracheos tomy.
The third approach is bariatric surgery (i.e., surge ry for weight reduc tion). Bariatric surgery includ es variou s form s of gastroplasty and gastric and intestinal bypa ss. For morbidly obese patients in whom the GSA appears to be at least in part secondary to obes ity, these modalities of treatment might have a role as either a sole therapy or in conj unction with other surgical and nonsurgical approaches. Although some of the initi al weight reduction tends to be reversed over time, there appears to be a significa nt long-term reductio n in weig ht and a decrease in GSA sever ity.I':"
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For more information Circle 116 on Reader Service Card Volume 78, Number 9 705 SHER Finally, the fourth approach is sur gery to implant a pacemaker for pacing pharyn geal mu scles (i.e ., the genioglossus) to dilate the upper airway."
The effi cacy of various ther apeutic approac hes has been measured by the amount of improvem ent in polysomn ographic parameters such as the respi ratory disturb ance index (apneas and hyp opneas per hour) and the sleep frag me ntation index (microa rousa ls per hou r). It is possible that the application of an indirect mea sure of efficacy, the Pcrit decrement, cou ld hav e some clinical benefit in patient selec tion and treatment evaluation. In general, Pc rit mu st be below -5 ern HzO to eliminate SDB . 31 Three examples of the app roximate decrement in Pcrit that can be achieved by different interventions are -6 em Hp through the loss of 15% of body weight ; -3 to -4 em HzO through protriptyline treatment; and -4 to -5 cm Hz°through the avoidance ofsleeping in the supine position . Th e decrement in Pcrit achieved by variou s surgical measures in specific clinical settings remains unknown, but it might prov ide useful inform ation for pat ient and procedure selection."
With the complexity of assessment and therapy for OSA , it seem s clear that a multidiscipl inary approach that coo rdin ates input from dive rse beh avio ral, medical, surgical, and dental specialists would be of valu e. As OSA is largel y an upp er airway disord er, there is a potenti al leadership role fo r the otolaryngologist, who is the recognized expert in assessment and treatm ent of disorders of the upper airway.
